Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)

German double-blind RCT reported sorafenib maintenance therapy reduced risk of relapse or death vs placebo (n=83; median follow up 41.8 months; HR 0.39; 95% CI, 0.18 to 0.85; P = 0.013).


Journal of Clinical Oncology